AstraZeneca PLC (LON:AZN) stock price target reduced to 4,600.00GBX, issued a research note today by JP Morgan Cazenove
- Updated: November 27, 2016
Yesterday AstraZeneca PLC (LON:AZN) traded -1.12% lower at 4,246.50GBX. AZN’s 50-day average is 4,627.08GBX and its two hundred day average is 4,581.14GBX. With the last close down -7.15% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the same period. Volume of trade was down over the average, with 365,177 shares of AZN changing hands under the typical 2,619,060
In a report released on Monday November 28, 2016 JP Morgan Cazenove reduced the stock price target of AstraZeneca PLC (LON:AZN) from 4,900.00GBX to 4,600.00GBX indicating a possible upside of 0.08%.
Previously on 11/23/2016, HSBC reported on AstraZeneca PLC (LON:AZN) held steady the target price at 4,700.00GBX. At the time, this indicated a possible upside of 0.11%.
With a total market value of 0 GBX, AstraZeneca PLC has price-earnings ratio of 21.82 with a one year low of 3,680.00GBX and a one year high of 5,505.00GBX .
A total of 29 analysts have released a report on AstraZeneca PLC. Four analysts rating the company a strong buy, fourteen analysts rating the company a buy, thirteen analysts rating the company a hold, two analysts rating the company a underperform, and finally one analyst rating the company a sell with a 12-month price target of 61.96GBX.
More About AstraZeneca PLC (LON:AZN)
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.